All Oncology News

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

The phase III TAHOE trial evaluating second-line rovalpituzumab tesirine as a treatment for patients with advanced small cell lung cancer has stopped enrollment as recommended by an Independent Data Monitoring Committee.

The Association of Community Cancer Centers announced today that it has partnered with Pfizer Global Medical Grants to award more than $1.8 million in funding to 15 projects that are aimed at improving the quality of breast cancer patient care.

The addition of brentuximab vedotin to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma.

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

The Association of Community Cancer Centers announced the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies.

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Trung Nguyen, DO, MBA, discusses the evolving options for the treatment of patients with newly diagnosed advanced ovarian cancer.

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

The FDA has approved gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

The FDA has approved the first rituximab biosimilar, CT-P10, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

Amer Karam, MD, discussed surgical options for patients with advanced-stage ovarian cancer and the emergence of neoadjuvant chemotherapy.

The European Commission has granted approval to the biosimilar Ziextenzo, a biosimilar for pegfilgrastim, as a treatment to reduce the duration of neutropenia and incidence of febrile neutropenia that is associated with anticancer chemotherapy.

Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.

The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK-positive non–small cell lung cancer who were previously treated with crizotinib (Xalkori).

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve overall survival versus placebo as a maintenance therapy for patients with extensive-stage small cell lung cancer without disease progression following frontline platinum-based chemotherapy.

The FDA has approved larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion.

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.